ALKERMES reported $480.13M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 243M 25M Sep/2026
J&J USD 25.4B 89M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Otsuka Holdings JPY 710.05B 8B Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026